Targeted exome sequencing for mitochondrial disorders reveals high genetic heterogeneity by unknown
DaRe et al. BMC Medical Genetics 2013, 14:118
http://www.biomedcentral.com/1471-2350/14/118RESEARCH ARTICLE Open AccessTargeted exome sequencing for mitochondrial
disorders reveals high genetic heterogeneity
Jeana T DaRe1†, Valeria Vasta2†, John Penn2, Nguyen-Thao B Tran2 and Si Houn Hahn2,3*Abstract
Background: Mitochondrial disorders are difficult to diagnose due to extreme genetic and phenotypic
heterogeneities.
Methods: We explored the utility of targeted next-generation sequencing for the diagnosis of mitochondrial disorders
in 148 patients submitted for clinical testing. A panel of 447 nuclear genes encoding mitochondrial respiratory chain
complexes, and other genes inducing secondary mitochondrial dysfunction or that cause diseases which mimic
mitochondrial disorders were tested.
Results: We identified variants considered to be possibly disease-causing based on family segregation data and/or
variants already known to cause disease in twelve genes in thirteen patients. Rare or novel variants of unknown
significance were identified in 45 additional genes for various metabolic, genetic or neurogenetic disorders.
Conclusions: Primary mitochondrial defects were confirmed only in four patients indicating that majority of patients
with suspected mitochondrial disorders are presumably not the result of direct impairment of energy production.
Our results support that clinical and routine laboratory ascertainment for mitochondrial disorders are challenging
due to significant overlapping non-specific clinical symptoms and lack of specific biomarkers. While next-generation
sequencing shows promise for diagnosing suspected mitochondrial disorders, the challenges remain as the underlying
genetic heterogeneity may be greater than suspected and it is further confounded by the similarity of symptoms with
other conditions as we report here.
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Targeted exomeBackground
Patients with mitochondrial diseases present with widely
variable phenotypes that can affect any organ, at any age.
This clinical variability and a lack of reliable diagnostic
tests can make diagnosing these disorders very challenging.
Currently, the diagnosis relies upon the enzymatic analysis
of respiratory chain complexes (RCC) in muscle biopsy
tissues [1,2]. Unfortunately, clinical laboratories have
considerable differences in their RCC assay protocols and
methods of interpretation, leading to inaccurate diagnoses
that can affect the quality of patient care [3-5].* Correspondence: sihahn@uw.edu
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reproduction in any medium, provided the orRecently, targeted next-generation sequencing (NGS)
has been utilized to diagnose patients with several types
of disorders [6-11]. For mitochondrial disease, NGS can be
used not only to examine genes that have been classically
considered to cause disease, such as RCC subunits and
assembly factors, but also to analyze genes that are
suspected to cause mitochondrial dysfunction, or genes
causing conditions that mimic mitochondrial disease [12].
Over 200 nuclear genes have been identified that cause
mitochondrial disease, and the list continues to grow as
over 1500 genes have been identified controlling mitochon-
drial structure and function [13,14]. We recently explored a
panel of ~900 known and candidate disease genes for 26
patients with known or suspected mitochondrial disorders
[15]. This study was successful in demonstrating both
the analytical sensitivity and the clinical utility of NGS
by diagnosing several of the patients included. Here, wetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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364 known genes causing mitochondrial disease or similar
disease, and 83 candidate genes expected to be involved in
critical mitochondrial functions, such as RCC subunits
and tRNA synthetases. This gene panel was offered to
physicians as a commercially available clinical diagnostic
assay through Transgenomic, Inc. The samples were proc-
essed, analyzed, and interpreted at a CLIA-approved labora-
tory at Seattle Children’s Research Institute, and the final
report was provided through Transgenomic, Inc. Here, we
present data from the first 148 patients.
Methods
Patients
148 patients were referred by experts in mitochondrial
medicine, and all patients had diagnosed or suspected
mitochondrial disorders according to the physicians.
Limited clinical information was provided for the patients
with the test requisition, and the clinical presentations
that were provided varied widely. The most common
clinical findings included developmental delay and hypo-
tonia, and other common findings are listed (Table 1). Not
enough clinical and laboratory information were provided
to independently determine if patients fulfilled Modified
Walker Criteria for diagnosis of mitochondrial disorders
[16], however about 36% of patients did have abnormal
RCC enzymes activity and/or abnormal muscle pathology
(Table 1). Some patients had undergone previous genetic
testing, including mitochondrial DNA (mtDNA) sequen-
cing and single nuclear gene testing. In the few cases where
results were provided for these tests, they were either con-
sidered negative or contained variants of unknown signifi-
cance. The majority of patients were under the age of
18 years (83%) and the age range was <1 year to 68 years.
Parental samples were also submitted following the release
of the proband’s report as recommended to further eluci-
date the significance of variants found. Written Informed
consent was obtained from all patients, or their parents
on the behalf of the patients under 18 years of age, whenTable 1 Clinical and laboratory characteristics of patients
Clinical phenotype Percentage (%)
Developmental delay 53
Abnormal RCC enzymes activity 21







Dystonia 4testing were ordered by the patient’s physician. The In-
stitutional Review Board at Seattle Children’s Hospital
approved the study (#14631).
DNA capture and sequencing
A DNA library was prepared for each sample using an Illu-
mina Genome DNA Sample preparation kit (Illumina, San
Diego, CA). The exons of the genes of interest (Additional
file 1: Table S1) were captured by in-solution hybridization
using custom made probes (SureSelect, Agilent, Santa
Clara, CA).
The gene panel run from June 2011 to August 2011
consisted of 418 genes, and then was expanded to 447
genes in September 2011. These genes include all of the
nuclear-encoded structural components of the mitochon-
drial respiratory chain complexes (n = 89), as well as
mitochondrial respiratory chain complexes assembly
factors (n = 29), mitochondrial carriers (n = 17), genes for
mitochondrial DNA synthesis, transcription, translation,
mitochondrial biogenesis and dynamic (n = 71), genes for
mitochondrial enzymes (n = 114), and other genes that may
affect mitochondrial function secondarily or that cause
similar clinical phenotypes (n = 127) (Additional file 1:
Table S1). Some genes are overlapping in the categories.
mtDNA sequencing was not included in this test as it is
available as a separate and less costly test. Sequencing was
performed by a Genome Analyzer IIx instrument (Illumina,
San Diego, CA) using single-end reads and one sample
per lane on the 8-lanes flow-cell.
Data analysis
Reads were aligned using Burrows-Wheeler Aligner (BWA)
[17]. Data were analyzed with the Genome Analysis Toolkit
(GATK) (Broad Institute, Cambridge, MA) Unified Gen-
otyper (version 1.0.4013) and Variant Filtration Walker
to filter the variants that meet quality control requirements.
Insertion and deletions were analyzed with Dindel (GATK
version 1.0.5336) [18]. Variants found within the targeted
regions (exons +/− 20 bp on either side of the exon)
were further evaluated for their possible clinical significance
by cross-referencing to dbSNP and the 1000 genomes
browser. An internal database of polymorphisms was
also used during this analysis. For variants in genes with
autosomal dominant (AD) and X-linked (XL) disease inher-
itance, we used the minor allele frequency (MAF) cut-off of
0.2%, and for variants in genes with autosomal recessive
disease (AR) inheritance, we used the MAF cut-off of
0.5%. Variants that exceeded these frequencies were not
considered as potential mutations, even if they were re-
corded as such in the Human Gene Mutation Database
(HGMD). Finally, variants were searched in the HGMD
by internet search engine [19,20]. Variants identified as
possibly disease causing were confirmed by Sanger sequen-
cing using a Big-Dye Terminator v3.1 Kit on an ABI3130xl
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Carlsbad, CA). We analyzed the non-synonymous single
nucleotide substitutions with PolyPhen 2 (Polymorphism
Phenotyping) to predict the possible impact of amino
acid substitutions on the structure and function of a
protein [21].
In each patient’s report, parental testing was recom-
mended and offered at no additional charge to further
elucidate the significance of all confirmed, possibly disease
causing variants. This parental testing was performed by
Sanger sequencing as described above, and results were
used to further interpret variants found in the proband.
Quality control metrics
A variety of quality control metrics were used to ensure that
patient runs were of the highest quality. These included
an examination of the percentage of reads mapping to the
human genome, the percentage of reads mapping to the
targeted regions, the average read depth of targeted regions,
and the percentage of targets with greater than an average
of 20× coverage per base with a quality score of Q ≥ 30.
An external control was included in the eighth lane of every
sequencing run and consisted of a previously characterized
HapMap sample (Coriell Institute, Camden, NJ).
Results
Sequencing and quality control
On average, 67.4% of reads aligned to the human genome,
and 61.2% aligned to the targeted regions. Average coverage
of the targeted regions was 147× per base, and on average,
95.6% of targets had greater than 20× coverage per base
with a score of Q ≥ 30. Internal and external controls were
used to verify the quality of each sequencing run. In the
external HapMap control, we identified on average 164.7
variants per run (95.7%) of the 172 previously characterized
SNPs in this HapMap sample within the targeted regions.
We also used a panel of 200 SNPs with high minor allele
frequencies in the first 20 patients as an internal sensitivity
control for all samples, and we identified an average of
194.3 (94.7%) of the SNPs in each patient.
Variants in targeted genes
On average, we found 553 variants per patient in the tar-
geted regions. Synonymous single nucleotide substitutions
were the most common, followed closely by intronic/UTR
(limited to 20 nucleotides from the exon boundary), and
missense single nucleotide substitutions (Additional file 2:
Figure S1). Nonsense and canonical splice-site single
nucleotide substitutions and insertion/deletion variants
were far less common among patients. After all variants
were compared to public SNP databases, and an internal
SNP database, most were eliminated from consideration
because they were highly prevalent in these cohorts. Vari-
ants were also searched for in HGMD, and several observedvariants were considered to be misannotated as pathogenic,
given their high MAF value. Following this comparison,
on average 6.5 variants of interest were identified per pa-
tient. Most of these were single heterozygous variants of
unknown significance in genes with AR disease inheritance.
Suspected disease-causing alterations and variants
of unknown significance in patients
We identified variants considered to be possibly disease-
causing based in twelve genes in thirteen patients (Table 2).
These variants were suspected to be disease-causing based
on their low MAF, and their appropriate segregation within
parental samples; eleven of the 21 variants had also been
published as disease-causing mutations (Table 2). While
we suspect that these variants are disease-causing, the true
significance of each variant cannot be determined without
functional studies. Even when variants have been published
as disease-causing mutations, it is known that these vari-
ants can later be classified as benign. In all clinical reports,
we indicate that clinical correlation is required to confirm
the molecular diagnosis and that the results of this test
are not intended to be used as the sole means for patient
diagnosis or patient management decisions and must be
used in conjunction with the patient’s clinical history and
any previous analysis of appropriate family members.
The variants identified as possibly disease-causing were
located in the genes MTFMT (Leigh syndrome) [22,23],
NDUFS2 (Mitochondrial complex I deficiency) [24], NDU-
FAF5 (Mitochondrial complex I deficiency) [25], ETFB
(Glutaric acidemia IIB) [26], PANK2 (Neurodegeneration
with brain iron accumulation) [27], PCK2 (Phosphoenol-
pyruvate carboxykinase deficiency) [28], SLC3A1 (Cys-
tinuria) [29], TYMP (Mitochondrial neurogastrointestinal
encephalopathy) [30], OTC (Ornithine transcarbamylase
deficiency) [31], SPAST (Spastic paraplegia 4) [32], SLC12A3
(Gitelman syndrome) [33] and CLN6 (Ceroid lipofuscino-
sis 6) [34]. CLN6 and other non mitochondrial nuclear
genes were included in our panel as the associated clinical
presentation can be easily confused with mitochondrial
disease. PolyPhen-2 predictions for these variants are listed
in Table 2. These predictions are provided for reference
only, and were not used in the classification of variants,
as in silico prediction models are known to not always
be accurate [35-37].
Variants of unknown significance were identified in genes
previously implicated in mitochondrial disorders or in
conditions that present with a similar phenotype in 67
patients (Additional file 3: Table S2 variants without family
segregation data, Additional file 4: Table S3 and Additional
file 5: Table S4 variants with decreased suspicion after
parental testing). To elucidate the significance of these
novel or rare variants, parental testing was recommended.
However, we received parental samples for only 30 of
the 83 cases for which testing was suggested. Of the 15
Table 2 List of disease with possible disease-causing alterations detected in patients










RCC subunit and assembly factor




Ser152del — — — Paternal —
875 T > C Met292Thr 150667550 <0.01 CM094573 Maternal Possibly damaging
2 NDUFAF5 Mitochondrial complex 1
deficiency (252010)
AR NM_024120.4 164A > G Gln55Arg — — — Maternal Probably damaging
327 + 3A > G — — — Paternal
mtDNA synthesis, transcription, translation, mitochondrial biogenesis and dynamic
3* MTFMT Leigh syndrome (256000) AR NM_139242.3 626G > A Ser209Leu 201431517 0.1 CS117162 Paternal Possibly damaging-
998G > C Ser333Ter — — Maternal —
4 TYMP Mitochondrial DNA depletion
syndrome 1 (MNGIE type) (603041)
AR NM_001953.3 1160G > A
homozygote
Gly387Asp — — CM055161 — Probably damaging
Mitochondrial enzymes
5* ETFB Glutaric acidemia IIB (231680) AR NM_001014763.1 235G > A Val79Ile 140608276 0.4 — Maternal Benign
565C > T Arg189Cys 147353781 0.3 — Paternal Possibly damaging
6 PANK2 HARP syndrome (607236) /
Neurodegeneration with brain
iron accumulation 1 (234200)
AR NM_153638.2 137A > T Asp46Val 148036492 0.2 — Maternal Benign
1561G > A Gly521Arg 137852959 <0.02 CM014248 Paternal Probably damaging
7* PCK2 PEPCK deficiency, mitochondrial
(261650)
AR NM_004563.2 731G > A Arg244Gln — <0.02 — Not in mother; father not
sequenced
Possibly damaging
1756G > A Gly586Ser 61737098 0.4 — Maternal Possibly damaging
8* OTC Ornithine transcarbamylase
deficiency (311250)
X-linked NM_000531.5 298 + 5G > C
hemizygote
— 72554348 0.2 CS063357 Male —
Other genes that affect mitochondrial function or that cause similar clinical phenotypes
9*/13 SPAST Spastic paraplegia 4 (182601) AD NM_014946.3 1625A > G Asp542Gly 142053576 <0.05 CM054864 — Benign
10 CLN6 Ceroid lipofuscinosis (CLN) 6
(601780)/ CLN Kufs type
(204300)
AR NM_017882.2 278 T > C Thr93Met 150001589 <0.04 CM120905 Maternal Probably damaging
775G > A Gly259Ser 150363441 <0.02 Paternal Probably damaging
11 SLC12A3 Gitelman syndrome (263800) AR NM_000339.2 322C > T Arg108Trp — — CM117057 — Possibly damaging
965C > T Ala322Val 142679083 0.5 CM117024 — Benign
12* SLC3A1 Cystinuria (220100) AR NM_000341.3 241C > T Arg81Cys 149813423 <0.02 CM090053 Maternal Benign
1400 T > C Met467Thr 121912691 0.4 CM941280 Paternal Benign
a All variants listed were heterozygous, except where notated otherwise.
b Prediction by Polyphen2 HumVar model.
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able to confirm that eight of them were in trans, therefore
consistent with AR disease inheritance (Table 2).
With regard to the genes with AD disease inheritance,
19 of 20 variants tested in parental samples were identified
in one of the patient’s parents (Additional file 5: Table S4)
and a KIF1B variant was tested only in the patient’s father
as a maternal sample was unavailable. If a variant was found
in both the patient and the patient’s presumably healthy
parents, the suspicion of its pathogenicity was greatly
reduced; however, it is still possible that incomplete pene-
trance or differences in expression could explain finding a
pathogenic mutation in a healthy parent.
One known mutation in the OTC gene (Table 2) and
seven variants of unknown significance in six genes were
detected with XL disease inheritance including DCX
(lissencephaly), PDHA1 (PDH deficiency), ABCD1 (X-linked
adrenoleukodystrophy), MECP2, CDKL5 (Rett syndrome),
and SLC6A8 (creatine transport defect) (Additional file 1:
Tables S2 and Additional file 4: Table S3). We received
parental samples to test only two of these alterations
(CDKL5, DCX) (Additional file 4: Table S3). Both variants
were found to be in the patient’s mothers, thereby reducing
the likelihood of these variants being pathogenic. Never-
theless, the CDKL5 variant was still suspicious due to
the clinical phenotype of the patient, since the referring
physician considered his disease to be consistent with
Angelman syndrome, and previously ruled out UBE3A
methylation and sequence defects. Skewed X-inactivation
in the patient’s mother could explain the presence of the
variant in the healthy mother, if it is indeed pathogenic.
It is also possible that this particular variant only mildly
affects protein function which can be overcome in a female,
but may be detrimental in a male.
Discussion
Diagnosis of mitochondrial disease by NGS of targeted
gene panels has been explored on a research basis over
the past years [2,10,11,15]. This work has proven to be
highly effective in diagnosing patients, and identifying
new disease genes [2,11,15,22,38-41]. This technology is
providing insights into the genetic basis of diseases that
often remain undiagnosed even after extensive clinical
workup [42]. The reliability of our approach has been
previously demonstrated from our earlier research studies
[10,15], and is similar to the approaches used for the
diagnosis of mitochondrial disorders and other inborn
errors of metabolism in other laboratories [2,40,43,44].
This approach has very high analytical sensitivity and
specificity as demonstrated by our quality control metrics
and use of internal and external controls. The clinical
sensitivity and specificity of the approach are less easily
defined. Our classification approach utilizes conservative
minor allele frequency cut-offs to insure that diseasecausing variants are not removed from consideration.
While this does allow for many rare, benign polymor-
phisms to be reported as variants of unknown significance,
we must rely on the patient’s physician to determine if
these variants fit the patient’s clinical presentation.
In this clinical study, patient samples were submitted
by physicians, most of whom were experts in the field of
mitochondrial medicine and ordered this test because
other diagnostic avenues had been unsuccessful and
mitochondrial disease was still suspected. As a result,
this patient cohort is more representative of the wide
variety of patients that are considered to have suspected
mitochondrial disease in comparison to the research studies
of the past.
Our data highlights the great underlying genetic hetero-
geneity of suspected mitochondrial disease, but also the
difficulty that even experienced physicians endure when
attempting to define mitochondrial disorders. Of note,
possible disease-causing variants, confirmed by parental
samples analysis, were found in only one gene that en-
codes an oxidative phosphorylation subunit of complex I
(NDUFS2) and one gene for the assembly of the complex
I (NDUFAF5). In a total of 148 patients we analyzed, there
was only one additional gene SCO2 in the category of
primary mitochondrial disease causative genes, with vari-
ants that we classified as of unknown significance as we
did not receive parental samples, but most likely associated
with disease.
Our results indicate that the majority of patients that
cannot obtain a molecular diagnosis by traditional methods
(RCC enzyme assay), have disease that is probably not the
result of direct impairment of energy production as we
observed in our previous study [15]. Instead, their disease
may be caused by secondary inhibition of proper mito-
chondrial function [30,45,46]. This observation is consist-
ent with other studies that utilized targeted sequencing on
patients with biochemically confirmed defects [2,15,23].
Other NGS studies have also indicated that suspected
“mitochondrial patients” were actually affected by con-
ditions caused by mutations in genes that don’t impair
mitochondria function [47,48]. While we can’t entirely
exclude that some patients may have mutations in mtDNA,
nuclear genes are primarily causative for pediatric cases,
which are the majority of the patients studied here [1]. The
requisition forms for the patients with variants listed in the
Tables indicated that 35 of them had mtDNA sequenced
with either normal or inconclusive results.
From our observation, it appears that the clinical differ-
ential diagnosis for mitochondrial disease could be even
more challenging, as the diagnostic spectrum is much
wider than previously thought. Some of our patients could
have been diagnosed by standard biochemical or genetic
studies, without NGS sequencing. Unfortunately, the lack
of clinical phenotypes that are specific to these diseases
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biochemical studies should be ordered for each case. A
good example is represented by the patient affected by
CLN6, a lysosomal storage disorder in which the clinical
presentations can easily mislead to focus on mitochondria,
leading to muscle biopsy and RCC assay.
While it is undoubtedly important to perform family
segregation analysis for the accurate and appropriate
interpretation of novel variants, we could not obtain
more parental samples in this study as some of parents
were not involved in patient’s care. We can nevertheless
consider that even when definitive diagnoses cannot be
made in the absence of family segregation supporting
data, the results can still guide physical examinations
or additional laboratory tests to look for signs specific
to the diseases for which possibly pathogenic variants were
found. Some examples include GAA (Pompe disease),
HLCS (Holocarboxylase synthetase deficiency), ABCD1
(X-linked adrenoleukodystrophy), PC (Pyruvate carboxyl-
ase deficiency), UBE3A (Angelman syndrome), ASL (Argi-
ninosuccinic aciduria), or ZFYVE26 (Spastic paraplegia 15)
(Additional file 3: Table S2). Presumptive diagnosis can
prompt recommended interventions, including diet modi-
fication for certain patients such as for ornithine transcar-
bamylase deficiency, one of the urea cycle disorders. It is
unfortunate that we cannot provide further details on any
follow-up biochemical tests that were recommended to
the referring physicians. The nature of clinical testing does
not allow for us to regularly follow-up on patients tested
and how our results affected their care.
Our results highlight the need to have better means to
define the significance of variants found. For instance,
the variants of unknown significance in genes with AD
inheritance were also found in majority of one of presum-
ably healthy parents. While this cannot entirely rule out
the possibility of pathogenic involvement, only functional
studies can truly assess the significance of these variants.
This problem is an even larger issue when whole exome
or whole genome sequencing data are interpreted.
Of interest, we have observed that many patients had
possibly disease-causing variants in multiple genes. This
suggests that some patients with suspected mitochondrial
disease may be caused by oligogenic factors, where many
mildly dysfunctional proteins may be insufficient to
cause disease alone, but when in combination can cause
disease in a patient. If this is possible, it even further
complicates the molecular diagnosis of these patients
and extended studies will be necessary to explore this
possibility. We also observed a substantial number of
VUS for Charcot-Marie-Tooth (CMT) disease, spinocer-
ebellar ataxia or spastic paraplegia related genes. While
these variants still require parental samples analysis to
determine the clinical significance, these conditions may
be an emerging group of mitochondrial disorders assupported by recent publications with evidence of mito-
chondrial dysfunction [49,50].
Conclusions
Our study revealed that a broader diagnostic spectrum
including neurodegenerative disorders or myopathy need
to be considered during the clinical work-up of suspected
mitochondrial patients and in developing future diagnostic
tests. It appears that the current standard diagnostic
algorithm along with the definition of mitochondrial
disorders may require substantial revision to ultimately
improve patient quality care. The clinical sensitivity of NGS
assays for mitochondrial disorders will be further improved
by targeting more genes and ultimately by whole exome
sequencing with adequate coverage in the near future.
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